Meeting
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
Authors
Teng Zhu
Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
Teng Zhu , Guochun Zhang , XueRui Li , YanHui Liu , Fangping Xu , Jian Zu , Ning Liao , Kun Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1062)
DOI
10.1200/jco.2014.32.15_suppl.1062
Abstract #
1062
Poster Bd #
155
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel.
First Author: Arvind Manohar Shinde
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2013 ASCO Annual Meeting
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
First Author: Lee Steven Schwartzberg
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao